BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35295035)

  • 1. Ethambutol-induced bullous skin lesions in
    Kollipara VK; Horowitz M; Lantz J; Nagy-Agren S
    Int J Mycobacteriol; 2022; 11(1):120-122. PubMed ID: 35295035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Distribution and drug resistance of nontuberculous
    Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
    Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
    Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
    Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
    [No Abstract]   [Full Text] [Related]  

  • 5. [Nontuberculous mycobacterial infections of the lung].
    Latshang TD; Lo Cascio CM; Russi EW
    Ther Umsch; 2011 Jul; 68(7):402-6. PubMed ID: 21728159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [THE GENETIC EXAMINATION OF BRONCHIAL LAVAGE ENABLES THE PROMPT DIAGNOSIS OF PULMONARY MYCOBACTERIUM KANSASII--A CASE REPORT].
    Mori M; Ageshio F; Kagawa H; Oshitani Y; Fujikawa T; Saito H; Sako H; Yano Y; Kitada S; Maekura R
    Kekkaku; 2015 Aug; 90(8):619-23. PubMed ID: 26665518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disseminated Mycobacterium kansasii infection with cutaneous lesions in an immunocompetent patient.
    Zhang M; Feng M; He JQ
    Int J Infect Dis; 2017 Sep; 62():59-63. PubMed ID: 28712930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013.
    Morimoto K; Hasegawa N; Izumi K; Namkoong H; Uchimura K; Yoshiyama T; Hoshino Y; Kurashima A; Sokunaga J; Shibuya S; Shimojima M; Ato M; Mitarai S
    Ann Am Thorac Soc; 2017 Jan; 14(1):49-56. PubMed ID: 27788025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated coinfection with Mycobacterium Avium complex and Mycobacterium Kansasii in a patient with idiopathic CD4
    Somboonviboon D; Thongtaeparak W; Suntavaruk P; Nasomsong W
    J Infect Chemother; 2023 Dec; 29(12):1167-1171. PubMed ID: 37562711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].
    Wagner D; Lange C
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1145-1151. PubMed ID: 32791550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined vs. single-drug studies of susceptibilities of Mycobacterium kansasii to isoniazid, streptomycin, and ethambutol.
    Tsang AY; Bentz RR; Schork MA; Sodeman TM
    Am J Clin Pathol; 1978 Nov; 70(5):816-20. PubMed ID: 717288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
    Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
    Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and treatment of atypical mycobacterial infections of the respiratory tract].
    Andréjak C; Lescure FX; Schmit JL; Jounieaux V
    Rev Mal Respir; 2011 Dec; 28(10):1293-309. PubMed ID: 22152937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid improvement of Mycobacterium kansasii pneumonia after rifabutin, isoniazid, and ethambutol: A case report.
    Kuo HI; Huang ST; Wu YH
    Kaohsiung J Med Sci; 2022 Nov; 38(11):1137-1138. PubMed ID: 36254860
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
    da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
    J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
    Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
    Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS].
    Ibarrola M; Baraia-Etxaburu J; Sánchez R; Teira R; Unzaga J; Miguel Santamaría J
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(2):80-2. PubMed ID: 11333577
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea.
    Park HK; Koh WJ; Shim TS; Kwon OJ
    Yonsei Med J; 2010 Jul; 51(4):552-6. PubMed ID: 20499421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium kansasii.
    Johnston JC; Chiang L; Elwood K
    Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28185617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis.
    Forslöw U; Geborek A; Hjelte L; Petrini B; Heurlin N
    Acta Paediatr; 2003 Aug; 92(8):910-5. PubMed ID: 12948065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.